Verinurad (BioDeep_00000015352)

Main id: BioDeep_00000184934

 


代谢物信息卡片


Verinurad

化学式: C20H16N2O2S (348.0932)
中文名称: 维立诺雷
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(C)(C(=O)O)SC1=C(C=NC=C1)C2=CC=C(C3=CC=CC=C32)C#N
InChI: InChI=1S/C20H16N2O2S/c1-20(2,19(23)24)25-18-9-10-22-12-17(18)16-8-7-13(11-21)14-5-3-4-6-15(14)16/h3-10,12H,1-2H3,(H,23,24)

描述信息

D018501 - Antirheumatic Agents > D006074 - Gout Suppressants
C26170 - Protective Agent > C921 - Uricosuric Agent

同义名列表

1 个代谢物同义名

Verinurad



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Susanne Johansson, David Han, Thomas Hunt, Karin Björck, Delia Florica, Michael Gillen, Jesse Hall, Fredrik Erlandsson. Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non-Asian participants. Pharmacology research & perspectives. 2022 06; 10(3):e00929. doi: 10.1002/prp2.929. [PMID: 35593744]
  • Zean Zhao, Jin Liu, Peihua Kuang, Jian Luo, Goverdhan Surineni, Xiaolin Cen, Ting Wu, Ying Cao, Pingzheng Zhou, Jianxin Pang, Qun Zhang, Jianjun Chen. Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia. European journal of medicinal chemistry. 2022 Feb; 229(?):114092. doi: 10.1016/j.ejmech.2021.114092. [PMID: 34998055]
  • Austin G Stack, Fredrik Erlandsson, Robert Terkeltaub. In Reply to 'Verinurad/Febuxostat and Nephrotoxicity'. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2021 09; 78(3):468-469. doi: 10.1053/j.ajkd.2021.05.009. [PMID: 34126126]
  • Raul Fernandez-Prado, Alberto Ortiz. Verinurad/Febuxostat and Nephrotoxicity. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2021 09; 78(3):468. doi: 10.1053/j.ajkd.2021.03.029. [PMID: 34126127]
  • Jacob Leander, Mikael Sunnåker, Dinko Rekić, Sergey Aksenov, Ulf G Eriksson, Susanne Johansson, Joanna Parkinson. A semi-mechanistic exposure-response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases. Journal of pharmacokinetics and pharmacodynamics. 2021 08; 48(4):525-541. doi: 10.1007/s10928-021-09747-y. [PMID: 33728547]
  • V Sashi Gopaul, Anna Vildhede, Tommy B Andersson, Fredrik Erlandsson, Caroline A Lee, Susanne Johansson, Constanze Hilgendorf. In Vitro Assessment of the Drug-Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters. The Journal of pharmacology and experimental therapeutics. 2021 08; 378(2):108-123. doi: 10.1124/jpet.121.000549. [PMID: 34074714]
  • Austin G Stack, David Han, Ronald Goldwater, Susanne Johansson, Nalina Dronamraju, Jan Oscarsson, Eva Johnsson, Joanna Parkinson, Fredrik Erlandsson. Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study. The Journal of clinical endocrinology and metabolism. 2021 04; 106(5):e2347-e2356. doi: 10.1210/clinem/dgaa748. [PMID: 33075806]
  • Austin G Stack, Nalina Dronamraju, Joanna Parkinson, Susanne Johansson, Eva Johnsson, Fredrik Erlandsson, Robert Terkeltaub. Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2021 04; 77(4):481-489. doi: 10.1053/j.ajkd.2020.09.009. [PMID: 33130235]
  • Diana I Jalal, Glenn M Chertow. Urate Lowering With Combination Therapy in CKD: Reason for Optimism or Einstein's Definition of Insanity?. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2021 04; 77(4):478-480. doi: 10.1053/j.ajkd.2020.11.007. [PMID: 33568321]
  • David Fitz-Patrick, Kent Roberson, Kiyoshi Niwa, Takabumi Fujimura, Koji Mori, Jesse Hall, Xiaohong Yan, Zancong Shen, Sha Liu, Yasushi Ito, Scott Baumgartner. Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials. Modern rheumatology. 2019 Nov; 29(6):1042-1052. doi: 10.1080/14397595.2018.1538003. [PMID: 30334639]
  • Xinrui Li, Jing Liu, Liang Ma, Ping Fu. Pharmacological urate-lowering approaches in chronic kidney disease. European journal of medicinal chemistry. 2019 Mar; 166(?):186-196. doi: 10.1016/j.ejmech.2019.01.043. [PMID: 30769179]
  • Jesse Hall, Michael Gillen, Xiaojuan Yang, Zancong Shen. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers. Clinical pharmacology in drug development. 2019 02; 8(2):179-187. doi: 10.1002/cpdd.463. [PMID: 29688628]
  • Martin Kankam, Jesse Hall, Michael Gillen, Xiaojuan Yang, Zancong Shen, Caroline Lee, Sha Liu, Jeffrey N Miner, Susan Walker, Vicki Clauson, David Wilson, Mai Nguyen. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout. Journal of clinical pharmacology. 2018 09; 58(9):1214-1222. doi: 10.1002/jcph.1119. [PMID: 29733447]
  • Jesse Hall, Michael Gillen, Sha Liu, Jeffrey N Miner, Shakti Valdez, Zancong Shen, Caroline Lee. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects. Drug design, development and therapy. 2018; 12(?):1799-1807. doi: 10.2147/dddt.s152659. [PMID: 29950814]